David Avigan

List of Publications by Year
in descending order

148 papers	5,629 citations	117625 34 h-index	85541 71 g-index
149 all docs	149 docs citations	149 times ranked	5892 citing authors

#	Article	IF	Citations
1	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology, 2016, 34, 2698-2704.	1.6	868
2	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet, The, 2021, 398, 314-324.	13.7	711
3	PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine. Journal of Immunotherapy, 2011, 34, 409-418.	2.4	270
4	Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses. Clinical Cancer Research, 2004, 10, 4699-4708.	7.0	227
5	Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity. Journal of Immunology, 2000, 165, 1705-1711.	0.8	211
6	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood, 2011, 117, 393-402.	1.4	199
7	Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients. Clinical Cancer Research, 2013, 19, 3640-3648.	7.0	199
8	Ciltacabtagene Autoleucel, an Antiâ€“B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. Journal of Clinical Oncology, 2023, 41, 1265-1274.	1.6	160
9	Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunology, Immunotherapy, 2013, 62, 39-49.	4.2	149
10	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Science Translational Medicine, 2016, 8, 368ra171.	12.4	140
11	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood, 2017, 129, 1791-1801.	1.4	130
12	Epsteinâ^'Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia, 2019, 33, 132-147.	7.2	126
13	Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 2002, 99, 2512-2517.	1.4	120
14	Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. Blood, 2014, 124, 291-291.	1.4	92
15	Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?. Blood, 2017, 129, 275-279.	1.4	85
16	Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clinical Cancer Research, 2021, 27, 1139-1149.	7.0	76
17	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 2004, 125, 343-352.	2.5	74
18	MUC1-C drives MYC in multiple myeloma. Blood, 2016, 127, 2587-2597.	1.4	71

#	Article	IF	Citations
19	Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. Blood, 2015, 126, 505-505.	1.4	67
20	Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. British Journal of Haematology, 2005, 129, 687-700.	2.5	65
21	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood, 2020, 135, 2182-2191.	1.4	62
22	Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. British Journal of Haematology, 2019, 185, 679-690.	2.5	52
23	Dendritic Cell-Tumor Fusion Vaccines for Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 6347S-6352S.	7.0	50
24	Dendritic Cell Therapies for Hematologic Malignancies. Molecular Therapy - Methods and Clinical Development, 2017, 5, 66-75.	4.1	50
25	Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells. Journal of Immunology, 2008, 181, 808-821.	0.8	49
26	MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. Cancer Research, 2013, 73, 5569-5579.	0.9	49
27	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Science Translational Medicine, 2021, 13, eabh1962.	12.4	49
28	Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opinion on Biological Therapy, 2005, 5, 703-715.	3.1	41
29	Vaccine therapy in hematologic malignancies. Blood, 2018, 131, 2640-2650.	1.4	41
30	Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood, 2019, 134, 606-613.	1.4	41
31	Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.. Journal of Clinical Oncology, 2016, 34, 8010-8010.	1.6	39
32	Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leukemia Research, 2004, 28, 1303-1312.	0.8	38
33	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. Blood, 2015, 126, 80-80.	1.4	38
34	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409-414.		37
35	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget, 2016, 7, 38974-38987.	1.8	36
36	Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma. Blood, 2021, 138, 549-549.	1.4	36

#	Article	IF	Citations
37	Dendritic/Tumor Fusion Cells as Cancer Vaccines. Seminars in Oncology, 2012, 39, 287-295.	2.2	35
38	Transduction of Malignant Plasma Cells with Three Costimulatory Molecules (TRICOM) Elicits Myeloma-Specific Immune Response in Vitro â€“ a Promising Strategy for Immunotherapy. Blood, 2012, 120, 1908-1908.	1.4	35
39	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <scp>MUC</scp>1. British Journal of Haematology, 2017, 176, 929-938.	2.5	34
40	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. Blood, 2008, 112, 92-92.	1.4	34
41	Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Research, 2019, 29, 446-459.	12.0	32
42	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood, 2015, 126, 354-362.	1.4	31
43	Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28. Journal of Immunotherapy, 2010, 33, 155-166.	2.4	30
44	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 305-305.	1.4	30
45	Current Treatment for Multiple Myeloma. New England Journal of Medicine, 2014, 371, 961-962.	27.0	26
46	MUC1 in hematological malignancies. Leukemia and Lymphoma, 2016, 57, 2489-2498.	1.3	22
47	<scp>MUC</scp>1â€€ is a target in lenalidomide resistant multiple myeloma. British Journal of Haematology, 2017, 178, 914-926.	2.5	20
48	Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. Blood Reviews, 2018, 32, 312-325.	5.7	19
49	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e122-e133.	4.6	19
50	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica, 2021, 106, 1330-1342.	3.5	19
51	Vaccination with DC/Multiple Myeloma Fusions in Conjunction with Stem Cell Transplantation.. Blood, 2007, 110, 578-578.	1.4	19
52	Cellular immunotherapy for multiple myeloma. Best Practice and Research in Clinical Haematology, 2008, 21, 559-577.	1.7	18
53	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
54	Fusions of Breast Cancer and Dendritic Cells as a Novel Cancer Vaccine. Clinical Breast Cancer, 2003, 3, S158-S163.	2.4	16

#	Article	IF	Citations
55	Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation IsÂAssociated with Selective Control of JC VirusÂReactivation. Biology of Blood and Marrow Transplantation, 2014, 20, 992-999.	2.0	16
56	Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.. Blood, 2009, 114, 1862-1862.	1.4	16
57	Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study. Blood, 2011, 118, 82-82.	1.4	16
58	A Multicenter Phase I Study of CTLA-4 Blockade with Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 3964-3964.	1.4	15
59	Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Advances, 2023, 7, 768-777.	5.2	15
60	Anti-myeloma activity and molecular logic operation by Natural Killer cells in microfluidic droplets. Sensors and Actuators B: Chemical, 2019, 282, 580-589.	7.8	14
61	Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Current Hematologic Malignancy Reports, 2015, 10, 395-404.	2.3	13
62	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy, 2017, 19, 272-284.	0.7	13
63	Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor. Blood Advances, 2018, 2, 1367-1370.	5.2	13
64	Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response to a Multiple Myeloma/Dendritic Cell Fusion Vaccine In Vitro. Blood, 2010, 116, 492-492.	1.4	13
65	MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. Journal of Cellular and Molecular Medicine, 2018, 22, 3887-3898.	3.6	12
66	A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget, 2016, 7, 26346-26360.	1.8	12
67	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Advances, 2022, 6, 2183-2194.	5.2	12
68	Dendritic Cell Cancer Vaccines: From the Bench to the Bedside. Rambam Maimonides Medical Journal, 2014, 5, e0024.	1.0	11
69	Prevention and treatment of relapse after stem cell transplantation with immunotherapy. Bone Marrow Transplantation, 2018, 53, 664-672.	2.4	11
70	First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2015, 126, 1838-1838.	1.4	11
71	Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial.. Journal of Clinical Oncology, 2015, 33, 8505-8505.	1.6	11
72	Can leukemia-derived dendritic cells generate antileukemia immunity?. Expert Review of Vaccines, 2006, 5, 467-472.	4.4	10

#	Article	IF	Citations
73	Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Molecular Cancer Therapeutics, 2017, 16, 2304-2314.	4.1	10
74	Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.. Blood, 2007, 110, 187-187.	1.4	10
75	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease. Blood, 2015, 126, 4218-4218.	1.4	10
76	Vaccination as Immunotherapy in Hematologic Malignancies. Journal of Clinical Oncology, 2021, 39, 433-443.	1.6	8
77	Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. Oncotarget, 2017, 8, 69237-69249.	1.8	8
78	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients. Blood, 2013, 122, 3928-3928.	1.4	7
79	The myeloma-developing regimens using genomics (MyDRUG) master protocol.. Journal of Clinical Oncology, 2019, 37, TPS8057-TPS8057.	1.6	7
80	Cellular immunotherapy as a therapeutic approach in multiple myeloma. Expert Review of Hematology, 2018, 11, 525-536.	2.2	6
81	Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8015-8015.	1.6	6
82	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e247-e255.	2.0	5
83	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2010, 116, 3060-3060.	1.4	5
84	DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. Blood, 2015, 126, 2549-2549.	1.4	5
85	A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 860-860.	1.4	5
86	CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study.. Blood, 2004, 104, 810-810.	1.4	5
87	A PMLâ€“PPAR-Î´ Pathway for Fatty Acid Oxidation Regulates Hematopoietic Stem Cell Maintenance Through the Control of Asymmetric Division.. Blood, 2012, 120, 2327-2327.	1.4	5
88	Role of Immune Therapies for Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1440-1447.	4.9	4
89	A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML). Blood, 2012, 120, 3627-3627.	1.4	4
90	Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8003-8003.	1.6	4

#	Article	IF	Citations
91	Challenges in vaccine therapy in hematological malignancies and strategies to overcome them. Expert Opinion on Biological Therapy, 2016, 16, 1093-1104.	3.1	3
92	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplantation, 2020, 55, 804-810.	2.4	3
93	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. Blood, 2004, 104, 751-751.	1.4	3
94	Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. Blood, 2010, 116, 906-906.	1.4	3
95	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. Blood, 2011, 118, 948-948.	1.4	3
96	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. Blood, 2012, 120, 578-578.	1.4	3
97	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. Blood, 2013, 122, 695-695.	1.4	3
98	Mucin-1 (MUC1) Oncoprotein in Multiple Myeloma Cells Inhibits the Th1 Responses By Down Regulating the Expression of Mir-200c and up-Regulating the PDL1 Expression. Blood, 2014, 124, 2072-2072.	1.4	3
99	Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). Blood, 2014, 124, 4737-4737.	1.4	3
100	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2021, 138, 264-264.	1.4	3
101	Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation. Bone Marrow Transplantation, 2020, 55, 1178-1180.	2.4	2
102	Parathyroid Hormone May Improve Autologous Stem Cell Mobilization Via the Stem Cell Niche.. Blood, 2005, 106, 1968-1968.	1.4	2
103	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. Blood, 2007, 110, 284-284.	1.4	2
104	CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma.. Blood, 2009, 114, 781-781.	1.4	2
105	MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia. Blood, 2015, 126, 2473-2473.	1.4	2
106	Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.. Blood, 2009, 114, 783-783.	1.4	2
107	Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin Lymphoma. Journal of Hematology (Brossard, Quebec), 2021, 10, 212-216.	1.0	2
108	A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 2759-2759.	1.4	2

#	Article	IF	Citations
109	Vaccine therapy and adoptive immunotherapy in hematologic malignancies. Best Practice and Research in Clinical Haematology, 2008, 21, 373-374.	1.7	1
110	Cancer vaccines in hematologic malignancies: advances, challenges and therapeutic potential. Expert Review of Vaccines, 2010, 9, 451-454.	4.4	1
111	Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. Ecological Management and Restoration, 2016, 30, 1-8.	0.4	1
112	Neoantigenâ€based vaccines as a promising strategy in cancer immunotherapeutics. Immunomedicine, 2021, 1, e1021.	0.7	1
113	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. , 1998, 83, 409.		1
114	Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. Blood, 2010, 116, 848-848.	1.4	1
115	Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Phase 2 and Long Term Efficacy, Safety and Immune Correlates. Blood, 2014, 124, 41-41.	1.4	1
116	90Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma. Blood, 2010, 116, 2866-2866.	1.4	1
117	Pure Red Cell Aplasia after ABO-Mismatched Allogeneic Stem Cell Transplantation Treated with Therapeutic Plasma Exchange and Rituximab. Blood, 2015, 126, 5453-5453.	1.4	1
118	Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T. Blood, 2021, 138, 2786-2786.	1.4	1
119	Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study. Blood, 2021, 138, 401-401.	1.4	1
120	Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. Blood, 2021, 138, 2830-2830.	1.4	1
121	Fc Receptor-Dependent Trogocytosis of CD39 Impacts Engraftment and Invasiveness of Acute Myeloid Leukemia Cells. Blood, 2021, 138, 3298-3298.	1.4	1
122	Therapeutic dendritic cell cancer vaccines in hematologic malignancies. Immunomedicine, 2021, 1, e1022.	0.7	0
123	Vaccination for cancer: Myth or reality. Immunomedicine, 2021, 1, e1026.	0.7	0
124	Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.. Blood, 2005, 106, 2788-2788.	1.4	0
125	Stimulation of Anti-Tumor Immunity Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28.. Blood, 2006, 108, 3715-3715.	1.4	0
126	Stimulation of Anti-Tumor Immunity Using Dendritic Cells Transduced with Fowl Pox Vector Expressing MUC-1 and Costimulatory Molecules (PANVAC-F).. Blood, 2006, 108, 5209-5209.	1.4	0

#	Article	IF	Citations
127	Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions.. Blood, 2007, 110, 1794-1794.	1.4	0
128	The Humanized Anti PD-1 Antibody, CT-011, Increases Specific CD4+ Effector/Memory and Memory T Lymphocytes in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Following Autologous Stem Cell Transplantation (AuSCT).. Blood, 2009, 114, 1216-1216.	1.4	0
129	A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation.. Blood, 2009, 114, 1148-1148.	1.4	0
130	MUC1 Inhibition Reverses the Poor Immunogenicity of Leukemia Stem Cells Rendering Them Susceptible to Immunotherapy. Blood, 2011, 118, 1883-1883.	1.4	0
131	Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes,. Blood, 2011, 118, 4066-4066.	1.4	0
132	Low Levels of 25-Hydroxyvitamin D Prior to Allogeneic Transplantation Correlate with the Development of Chronic Graft-Versus-Host Disease,. Blood, 2011, 118, 4063-4063.	1.4	0
133	Adoptive T Cell Therapy for Progressive Multifocal Leukoencephalopathy Using Sequential Ex-Vivo Stimulation with JCV Peptide Pulsed Dendritic Cells and Anti-CD3/CD28. Blood, 2011, 118, 2175-2175.	1.4	0
134	Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition. Blood, 2012, 120, 3583-3583.	1.4	0
135	STAT3 Inhibition Promotes Potent Th1 Responses By Down Regulating Pdl-1 Expression On Tumor Cells. Blood, 2013, 122, 3217-3217.	1.4	0
136	Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential. Blood, 2013, 122, 127-127.	1.4	0
137	MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. Blood, 2014, 124, 808-808.	1.4	0
138	Immunomodulatory Effect of SGI-110, a Novel Hypomethylating Agent in Acute Myeloid Leukemia (AML). Blood, 2014, 124, 2303-2303.	1.4	0
139	Delayed Platelet Engraftment after Umbilical Cord Blood Transplant: Relationship to Circulating Levels of Thrombopoietin. Blood, 2014, 124, 3862-3862.	1.4	0
140	Myeloid-Derived Suppressor Cells Are Expanded in Patients with AML and Are Dependent on MUC1 Expression. Blood, 2014, 124, 226-226.	1.4	0
141	Bone Marrow Stroma Protects Myeloma Cells from Cytotoxic Damage Via Induction of the Oncoprotein MUC1. Blood, 2014, 124, 3378-3378.	1.4	0
142	MUC-1 Regulates MiR34a Expression in Acute Myeloid Leukemia Cells Resulting in an Accumulation of Granulocytic Myeloid-Derived Suppressor Cells. Blood, 2015, 126, 643-643.	1.4	0
143	Immunomodulatory Effect of MUC1-C in Acute Myeloid Leukemia. Blood, 2015, 126, 3659-3659.	1.4	0
144	A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2015, 126, 2550-2550.	1.4	0

#	Article	IF	Citations
145	Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia. Blood, 2021, 138, 904-904.	1.4	0
146	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study. Blood, 2021, 138, 2691-2691.	1.4	0
147	Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances. Blood, 2021, 138, 737-737.	1.4	0
148	Advances in the development of a therapeutic cancer vaccine. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3 Suppl 1, S2-6.	4.9	0